Sanofi Said to Be in Advanced Talks to Acquire Actelion

The transcript discusses the interest of various drugmakers in acquiring Actelion, highlighting the negotiations with companies like J&J and Sanofi. It delves into the challenges faced during these negotiations, particularly focusing on the contingent value rights (CVR) as a key component of the deal structure. The discussion also covers the volatility of Actelion's stock price in response to different bids over the years, emphasizing the importance of reaching a successful agreement for shareholders.

What is the main focus of the negotiations mentioned in the text?

What challenges did the management face in reaching an agreement with J&J?

How does the contingent value play a role in the negotiations?

What has been the trend of the stock price during the negotiation process?

What are the expectations of shareholders regarding the potential deal?